DIO2-AS1: A Potential Drug Target and Biomarker (G100628307)

Target Name: DIO2-AS1

NCBI ID: G100628307

DIO2-AS1

Other Name(s): DIO2 antisense RNA 1

DIO2-AS1: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a crucial step in the development of new pharmaceuticals. DIO2-AS1, a protein expressed in various tissues of the body, has been identified as a potential drug target and biomarker. This protein plays a crucial role in the regulation of cell growth, differentiation, and survival, and its dysfunction has been linked to various diseases, including cancer.

DIO2-AS1: Structure and Function

DIO2-AS1 is a member of the Asparagine-Water-Asparagine (A-WAS) domain family, which is a common structural feature in proteins that are involved in various cellular processes, including cell signaling, cell adhesion, and tissue repair. The A-WAS domain is responsible for the formation of a specific hydrogen bonding pattern in the protein sequence, which is important for its stability and functions as a protein.

DIO2-AS1 functions as a negative regulator of the cell cycle, specifically in the G1 phase. It promotes the G1/S transition by inhibiting the activity of the G1-specific protein, p21 (CDK4), which is involved in cell growth and division. DIO2-AS1 also inhibits the activity of the S-phase protein, p22 (CDK6), which is involved in the completion of DNA replication. These inhibitions result in the accumulation of G1-specific and S-phase proteins in the cell, leading to the G1/S transition.

DIO2-AS1 has also been shown to play a role in the regulation of cell survival and apoptosis. It has been shown to promote the survival of cancer cells by inhibiting the activity of p53, a protein that is involved in cell apoptosis. Additionally, DIO2-AS1 has been shown to promote the growth of cancer cells by activating the A-WAS domain-containing protein, p16 (CDK4), which is involved in cell growth and survival.

DIO2-AS1 as a Potential Drug Target

The identification of DIO2-AS1 as a potential drug target is based on its involvement in the regulation of cell cycle and cell survival. DIO2-AS1 has been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer therapies.

One of the main advantages of DIO2-AS1 as a drug target is its specificity. Unlike many other potential drug targets, DIO2-AS1 has a clear and well-defined function, making it easier to develop new treatments. Additionally, DIO2-AS1 has been shown to play a role in the regulation of cell cycle and cell survival, which are crucial processes in cancer development.

Another advantage of DIO2-AS1 as a drug target is its availability. DIO2-AS1 is expressed in various tissues of the body, including human tissues, making it an attractive target for drugs that can be administered to patients without significant side effects.

DIO2-AS1 as a Potential Biomarker

DIO2-AS1 has also been identified as a potential biomarker for various diseases, including cancer. The regulation of cell cycle and cell survival by DIO2-AS1 is known to be disrupted in various diseases, including cancer.

One of the main potential benefits of DIO2-AS1 as a biomarker is its ability to be used as a diagnostic tool. By measuring the levels of DIO2-AS1 in cancer cells or tissues, researchers can monitor the effectiveness of new treatments and determine the impact of disease progression. Additionally, DIO2-AS1 has been shown to be downregulated in various

Protein Name: DIO2 Antisense RNA 1

The "DIO2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIO2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets